Published in Curr Pharm Des on January 01, 2005
Preoperative Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass | NCT00934843
Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovasc Res (2008) 1.80
TNFα in myocardial ischemia/reperfusion, remodeling and heart failure. Heart Fail Rev (2011) 1.47
Critical role of extracellular heat shock cognate protein 70 in the myocardial inflammatory response and cardiac dysfunction after global ischemia-reperfusion. Am J Physiol Heart Circ Physiol (2008) 1.24
Toll-like receptors: new players in myocardial ischemia/reperfusion injury. Antioxid Redox Signal (2011) 1.04
Tissue-specific effects of the nuclear factor kappaB subunit p50 on myocardial ischemia-reperfusion injury. Am J Pathol (2007) 1.04
Nasal vaccination with troponin reduces troponin specific T-cell responses and improves heart function in myocardial ischemia-reperfusion injury. Int Immunol (2009) 0.86
Gypenoside Protects Cardiomyocytes against Ischemia-Reperfusion Injury via the Inhibition of Mitogen-Activated Protein Kinase Mediated Nuclear Factor Kappa B Pathway In Vitro and In Vivo. Front Pharmacol (2016) 0.78
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature (2008) 10.73
Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension (2012) 6.70
MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation (2007) 6.41
Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med (2015) 6.00
Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation (2004) 3.38
MicroRNAs: novel regulators in cardiac development and disease. Cardiovasc Res (2008) 3.30
Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature (2012) 2.27
Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation (2008) 2.18
Activation of CD4+ T lymphocytes improves wound healing and survival after experimental myocardial infarction in mice. Circulation (2012) 2.14
Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes (2007) 2.12
Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol (2005) 1.99
MicroRNA-24 regulates vascularity after myocardial infarction. Circulation (2011) 1.98
Short communication: asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a microRNA-21-dependent mechanism. Circ Res (2010) 1.96
Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol (2011) 1.94
The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun (2012) 1.88
Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med (2007) 1.83
Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovasc Res (2008) 1.80
Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt. J Mol Cell Cardiol (2003) 1.80
Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction. Hypertension (2007) 1.68
Bone marrow molecular alterations after myocardial infarction: Impact on endothelial progenitor cells. Cardiovasc Res (2006) 1.65
Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. Circ Res (2007) 1.61
Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension (2011) 1.59
Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol (2003) 1.52
Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol (2008) 1.52
Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator. Eur J Heart Fail (2014) 1.52
Supramolecular nanostructures that mimic VEGF as a strategy for ischemic tissue repair. Proc Natl Acad Sci U S A (2011) 1.50
The dying stem cell hypothesis: immune modulation as a novel mechanism for progenitor cell therapy in cardiac muscle. J Am Coll Cardiol (2005) 1.43
Effects of physical exercise on myocardial telomere-regulating proteins, survival pathways, and apoptosis. J Am Coll Cardiol (2008) 1.43
Absence of NF-kappaB subunit p50 improves heart failure after myocardial infarction. FASEB J (2006) 1.42
Innate immunity and angiogenesis. Circ Res (2005) 1.42
Fractalkine promotes platelet activation and vascular dysfunction in congestive heart failure. Thromb Haemost (2013) 1.41
ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay. Thromb Haemost (2008) 1.40
Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation (2007) 1.37
Reverse epidemiology in systolic and nonsystolic heart failure: cumulative prognostic benefit of classical cardiovascular risk factors. Circ Heart Fail (2009) 1.35
Apoptosis repressor with caspase recruitment domain is required for cardioprotection in response to biomechanical and ischemic stress. Circulation (2006) 1.33
Monocytes/macrophages prevent healing defects and left ventricular thrombus formation after myocardial infarction. FASEB J (2012) 1.31
Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure. Cardiovasc Res (2003) 1.24
Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus. Atherosclerosis (2007) 1.24
Targeted deletion of caspase-1 reduces early mortality and left ventricular dilatation following myocardial infarction. J Mol Cell Cardiol (2003) 1.23
Attenuation of angiotensin II-induced vascular dysfunction and hypertension by overexpression of Thioredoxin 2. Hypertension (2009) 1.23
The role of natural IgM in myocardial ischemia-reperfusion injury. J Mol Cell Cardiol (2006) 1.22
Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction. Br J Pharmacol (2003) 1.20
Rapid regulation of platelet activation in vivo by nitric oxide. Circulation (2004) 1.17
A role for caspase-1 in heart failure. Circ Res (2007) 1.13
Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation (2011) 1.12
Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets. Circulation (2007) 1.11
Comparison of different miR-21 inhibitor chemistries in a cardiac disease model. J Clin Invest (2011) 1.10
Regulation of Toll-like receptor 4 expression in the lung following hemorrhagic shock and lipopolysaccharide. J Immunol (2002) 1.10
Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis. Curr Vasc Pharmacol (2008) 1.09
Novel therapeutic approaches to post-infarction remodelling. Cardiovasc Res (2012) 1.07
Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation (2008) 1.07
Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clin J Am Soc Nephrol (2009) 1.06
A signature of circulating microRNAs differentiates takotsubo cardiomyopathy from acute myocardial infarction. Eur Heart J (2013) 1.06
Ligand-dependent activation of ER{beta} lowers blood pressure and attenuates cardiac hypertrophy in ovariectomized spontaneously hypertensive rats. Cardiovasc Res (2007) 1.06
MicroRNA-22 increases senescence and activates cardiac fibroblasts in the aging heart. Age (Dordr) (2012) 1.06
Comparison of the American PPCM Registry Data With International Registries. J Am Coll Cardiol (2016) 1.05
Tissue-specific effects of the nuclear factor kappaB subunit p50 on myocardial ischemia-reperfusion injury. Am J Pathol (2007) 1.04
Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response. Hypertension (2008) 1.03
Vascular endothelial dysfunction and superoxide anion production in heart failure are p38 MAP kinase-dependent. Cardiovasc Res (2004) 1.02
CB(1) cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction. Br J Pharmacol (2003) 1.02
Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J (2012) 1.02
Left ventricular remodeling after myocardial infarction in mice with targeted deletion of the NADPH oxidase subunit gp91PHOX. Basic Res Cardiol (2005) 1.02
Harnessing the response to tissue hypoxia: HIF-1 alpha and therapeutic angiogenesis. Trends Cardiovasc Med (2002) 1.01
Novel role of the membrane-bound chemokine fractalkine in platelet activation and adhesion. Blood (2003) 1.01
Haeme oxygenase promotes progenitor cell mobilization, neovascularization, and functional recovery after critical hindlimb ischaemia in mice. Cardiovasc Res (2007) 0.97
Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the alpha-glucosidase inhibitor acarbose. FASEB J (2005) 0.95
Differential effects of organic nitrates on endothelial progenitor cells are determined by oxidative stress. Arterioscler Thromb Vasc Biol (2007) 0.95
Mitochondrial thioredoxin reductase is essential for early postischemic myocardial protection. Circulation (2011) 0.95
Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. Eur J Heart Fail (2014) 0.95
Growth hormone treatment improves markers of systemic nitric oxide bioavailability via insulin-like growth factor-I. J Clin Endocrinol Metab (2007) 0.95
Toll-like receptor signaling in the ischemic heart. Front Biosci (2008) 0.94
Circulating miR-423_5p fails as a biomarker for systemic ventricular function in adults after atrial repair for transposition of the great arteries. Int J Cardiol (2011) 0.94
Gene expression profiles in human cardiac cells subjected to hypoxia or expressing a hybrid form of HIF-1 alpha. Physiol Genomics (2002) 0.94
Improvement of endothelial dysfunction by selective estrogen receptor-alpha stimulation in ovariectomized SHR. Hypertension (2003) 0.94
Fractalkine is expressed in early and advanced atherosclerotic lesions and supports monocyte recruitment via CX3CR1. PLoS One (2012) 0.93
Tetrahydrobiopterin and eNOS dimer/monomer ratio--a clue to eNOS uncoupling in diabetes? Cardiovasc Res (2005) 0.93
Soluble guanylyl cyclase activation with HMR1766 attenuates platelet activation in diabetic rats. Arterioscler Thromb Vasc Biol (2006) 0.93
Reduced vascular NO bioavailability in diabetes increases platelet activation in vivo. Arterioscler Thromb Vasc Biol (2004) 0.93
Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability. Arterioscler Thromb Vasc Biol (2005) 0.93
Towards a re-definition of 'cardiac hypertrophy' through a rational characterization of left ventricular phenotypes: a position paper of the Working Group 'Myocardial Function' of the ESC. Eur J Heart Fail (2011) 0.92
Aerobic training in adults after atrial switch procedure for transposition of the great arteries improves exercise capacity without impairing systemic right ventricular function. Int J Cardiol (2013) 0.90
Endothelium-dependent and -independent relaxation and VASP serines 157/239 phosphorylation by cyclic nucleotide-elevating vasodilators in rat aorta. Biochem Pharmacol (2003) 0.90
Collagen accumulation after myocardial infarction: effects of ETA receptor blockade and implications for early remodeling. Cardiovasc Res (2002) 0.89
Endothelin receptor antagonists in heart failure: current status and future directions. Drugs (2004) 0.89
Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction. Cardiovasc Res (2005) 0.88
Caught in the act: in vivo molecular imaging of the transcription factor NF-kappaB after myocardial infarction. Biochem Biophys Res Commun (2006) 0.87
Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction. Cardiovasc Res (2003) 0.87
Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure. Pharmacol Res (2010) 0.85
Asymmetrical dimethylarginine--more sensitive than NT-proBNP to diagnose heart failure in adults with congenital heart disease. PLoS One (2012) 0.85
Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans. Eur Heart J (2010) 0.85
5-Lipoxygenase facilitates healing after myocardial infarction. Basic Res Cardiol (2013) 0.85
Telmisartan improves vascular function and reduces platelet activation in rats with streptozotocin-induced diabetes mellitus. Pharmacol Res (2007) 0.85
Angiopoietin-2 in adults with congenital heart disease and heart failure. PLoS One (2013) 0.85
Clopidogrel improves endothelial function and NO bioavailability by sensitizing adenylyl cyclase in rats with congestive heart failure. Basic Res Cardiol (2011) 0.84
The CX3C chemokine fractalkine induces vascular dysfunction by generation of superoxide anions. Arterioscler Thromb Vasc Biol (2006) 0.84
Improved endothelial function and reduced platelet activation by chronic HMG-CoA-reductase inhibition with rosuvastatin in rats with streptozotocin-induced diabetes mellitus. Biochem Pharmacol (2007) 0.84
Role of 5-lipoxygenase in myocardial ischemia-reperfusion injury in mice. Eur J Pharmacol (2007) 0.84